Abstract: Disclosed are polymer compositions, comprising (a) at least one polymer, and (b) at least one dialkylamide, with the exception of dialkylformamides and dialkylacetamides.

Abstract: The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases.

Abstract: Described herein is the synthesis and pharmacology of polymersomes containing one or more bioactive agents. The polymersome is generally derived from a polymer having the formula XY2, wherein X includes a hydrophilic group and Y includes a hydrophobic group. Also described herein are methods for making and using the polymersomes as drug delivery devices.

Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.

Abstract: The present disclosure relates to specific dimercaptoamides, reducing compositions for permanently reshaping keratin fibers comprising the dimercaptoamides, for instance, human keratin fibers such as the hair; and processes for reshaping keratin fibers comprising the application of said reducing compositions. The present disclosure also relates to processes for preparing the dimercaptoamides.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract: Compounds of the general formula and to the use thereof for controlling microorganisms are provided.

Abstract: We describe the functional cloning and the use of a non-fungal inositol phosphoryceraminde synthase (IPC synthase) in a screening assay for the identification of agents that target and antagonize the activity of IPC synthase.

Abstract: Compounds and methods related to NIR molecular imaging, in-vitro and in-vivo functional imaging, therapy/efficacy monitoring, and cancer and metastatic activity imaging. Compounds and methods demonstrated pertain to the field of peripheral benzodiazepine receptor imaging, metabolic imaging, cellular respiration imaging, cellular proliferation imaging as targeted agents that incorporate signaling agents.

Abstract: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of chemical and biological control for invasive molluscs in open waters, power plants, and drinking water treatment facilities under coldwater conditions.

Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.

Abstract: A photosensitive composition includes: (A) a resin containing a repeating unit corresponding to a compound represented by the following formula (I); the resin being capable of producing an acid group upon irradiation with an actinic ray or radiation: Z-A-X—B—R ??(I) wherein Z represents a group capable of becoming an acid group resulting from leaving of a cation upon irradiation with an actinic ray or radiation; A represents an alkylene group; X represents a single bond or a heteroatom-containing divalent linking group; B represents a single bond, an oxygen atom or —N(Rx)-; Rx represents a hydrogen atom or a monovalent organic group; R represents a monovalent organic group substituted by Y; when B represents —N(Rx)-, R and Rx may combine with each other to form a ring; and Y represents a polymerizable group.

Abstract: A composition comprising a copolymer having repeating units in any sequence of Formula I wherein Rf is a straight or branched perfluoroalkyl group having from about 1 to about 20 carbon atoms, or a mixture thereof, which is optionally interrupted by at least one oxygen atom, X3 is oxygen or X1, each X1 is independently an organic divalent linking group having from about 1 to about 20 carbon atoms, optionally containing an oxygen, nitrogen, or sulfur, or a combination thereof, G is F or CF3, A is an amide, j is zero or positive integer, X2 is an organic linking group, Y is O, N or S, h is zero when Y is N, and h is one when Y is O or S, Z is H, a straight or branched alkyl group having from about 1 to about 4 carbon atoms, or halide, B is H or wherein Rf, X1, X3, G, A, and j are as defined above, provided that when B is H, j is a positive integer, m is a positive integer, q is zero or a positive integer when Y is O, and q is a positive integer when Y is N or S, p is zero or a positive integer

Abstract: The present invention relates to the use of vanilloid receptor (VR) antagonists, and more particularly vanilloid receptor 1 (VR1) antagonist, as analgesics in the treatment and/or prohylaxis of cnidaria envenomations.

Abstract: An antidiarrhetic composition is provided which is efficacious against diarrhea, in particular, the predominant secretory diarrhea; an antidiarrhetic medicinal composition containing the same is also provided; a food containing the antidiarrhetic composition is also provided; and a method of preventing diarrhea using the same is also disclosed. The composition for relieving diarrhea is a cool composition capable of acting on the digestive tract in the recipient's body and inhibiting the secretion of the intestinal Cl?. In other words, a composition containing one or more kinds of cool act compounds. It may be provided by adding to medicines, foods or drinks.

Abstract: This invention relates to certain dioxodihydropyridine derivatives and certain methacrylic acid and furan derivative precursors thereof, processes for their preparation, pharmaceutical compositions containing such compounds and their use as anti-proliferative agents, especially tumour growth inhibitors and anti-cancer agents, antibiotics and/or antiviral agents.

Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.

Abstract: There are disclosed compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions.

Abstract: Use of an alkyl monoethanolamide having an alky chain length from 10 to 14 for the manufacture of a composition for the treatment of scalp itch.

Abstract: Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof represented by the general formula-(1) through novel intermediate compounds of general formula-(4).

Abstract: A therapeutic agent for the treatment of diabetic neuropathy which comprises (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]-ethyl]dimethylsulfonium p-toluenesulfonate of the formula (1) as an active ingredient.

Abstract: The present invention provides a method for preparing DMF for sucralose production, including, e.g., isolating DMF from a composition comprising DMF, water, and methanol, using a single-tower rectification system. In various embodiments of the present invention, the composition, after the removal of water and methanol, may be further dried/dehydrated, such as, by using a dehydration agent and/or filtration. The resulting substantially pure DMF may comprise at least about 98-99% DMF. The present invention further provides a method of preparing a composition comprising anhydrous sucrose for sucralose production, which may comprise mixing regular sucrose with a water-containing DMF composition, and drying the resulting sucrose-DMF composition. Also provided is a single-tower separation system for isolating DMF from a composition comprising DMF, water, and methanol.

Abstract: A process for the hydrogenation of carboxylic acids and/or derivatives, particularly amides, is described. The process includes reacting an acid or derivative such as an amide with a source of hydrogen in the presence of a catalyst system. The catalyst system obtainable by combining: (a) a source of ruthenium, and (b) a phosphine compound of general Formula I: (Formula I). The hydrogenation reaction is carried out in the presence of a low concentration of water or at low pressure or in the presence of a source of ammonia or the hydrogenation reaction is carried out in the absence of water or a combination of these factors is utilised. The invention also relates to the use of ammonia in the production of primary amines by hydrogenation of carboxylic acids and/or derivatives thereof or a process for the production of primary amines generally.

Abstract: The present application describes deuterium-enriched arformoterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: The present invention relates to a continuous method for functionalizing a carbon nanotube, and more specifically, to a continuous method for functionalizing a carbon nanotube by feeding functional compounds having one or more functional group into a functionalizing reactor into which a carbon nanotube mixture including oxidizer is fed under a pressure of 50 to 400 atm and a temperature of 100 to 600° C. to a subcritical water or supercritical water condition of a pressure of 50 to 40 atm by using a continuously functionalizing apparatus to obtain the functionalized products, such that the functional group of the functional compound can be easily introduced to the carbon nanotube, thereby increasing the functionalized effect of the carbon nanotube and increasing the dispersibility accordingly.

Abstract: This present invention provides materials for use as solid or concentrated chemical precursors for the production of organic peroxy acids (peracids). Organic peroxy acids are formed using a precursor according to the invention when they are combined with hydrogen peroxide or a hydrogen peroxide precursor such as a percarbonate or a perborate in aqueous medium. Organic peroxy acids, such as peroxyacetic acid, are used currently to disinfect medical equipment such as endoscopes and related items.

Abstract: The present invention is directed to a process for preparing ?-amino-?-hydroxycarboxamides. The process works with epoxycarboxamides of the formula 2 which are reacted with ammonia or other amines.

Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.

Abstract: This invention relates to the use of lactamide compounds of formula (I): CH3CH(OH)C(?O)NR1R2, where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and

Abstract: The invention relates to compounds of the formula (I) in which A1, A2, R1, R2, R3, R4, R5 and X are as defined in the description, to processes and intermediates for their preparation, and to their use for controlling pests.

Abstract: The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a vanilloid receptor agonists, capsaicinoid or capsaicinoid-like agonist capable of inducing hypothermia, thereby benefiting patients suffering from illnesses characterized by tissue anoxia.

Abstract: The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of bacterial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.

Abstract: Provided is a novel extractant for palladium capable of improving an extraction rate compared to the conventional extractant, DHS, and also capable of back-extracting palladium using an ammonia solution, and a method of separating and recovering palladium using the novel extractant.

Abstract: Method of purifying an open-chain N-vinyl compound by crystallization in a crystallizer, the crystallization being carried out from a melt of a mixture comprising open-chain N-vinyl compound at a pressure of 10?3 to 400 bar.

Abstract: A novel method is provided whereby a free organic acid can be produced particularly from an ammonium salt of an organic acid having a high melting point obtainable by bioconversion of a carbon source in the presence of a neutralizing agent, efficiently at a low cost, and the used material for reaction and a byproduct can be recycled for reuse without being disposed. An ammonium salt of organic acid A such as a dicarboxylic acid, a tricarboxylic acid or an amino acid is subjected to reactive crystallization by means of acid B such as a monocarboxylic acid satisfying the following formula (1), to separate free organic acid A in solid form: pKa(A)?pKa(B)??(1) where pKa(A) and pKa(B) represent ionization indices of organic acid A and acid B, respectively, provided that when they have plural values, they represent the minimum pKa among them.

Abstract: Devices are described that include a component comprised of a material having a structure of R1—C(O)—NX—R2, wherein each of R1 and R2 is independently a saturated alkyl having between 7-22 carbon atoms or an aryl, X is H or C(O)—Y, Y together with R1 forms a ring. The material is characterized by a single, sharp melting point, thus making it suitable for use, for example, in thermomechanical actuating devices or in temperature-indicating devices. Also described are compositions comprising two or more materials each having a structure of Rn1—C(O)—NH—R2 wherein, n is an identifying integer corresponding to a material in the composition; wherein for each material n in the composition, Rn1 and Rn2 are a saturated alkyl having between 7-22 carbon atoms, wherein for each material n Rn1 and Rn2 differ by one carbon atom, and wherein the number of carbon atoms in Rn2 of each material ndiffers by four or less.

Abstract: Methods of preparing compounds of formula (I): wherein Y, Y1, and R2 are defined herein; methods of making D-(threo)-1-aryl-2-acylamido-1-propanol compounds, D-(threo)-1-aryl-2-acylamido-3-fluoro-1-propanol compounds, and D-(threo)-1-aryl-2-acylamido-3-hydroxy-1-propanol compounds (collectively, “fenicol compounds”) from the compound of formula (I); and new fenicol compounds, which can be made using the method.

Abstract: The present invention relates to intermediates of rosuvastatin and processes for the production thereof.

Abstract: Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

Abstract: The invention relates to a pyridine oxide compound represented by formula (I), an optically active compound thereof, a salt thereof and a hydrate thereof, and, in the presence of the compound as a catalyst, performing 1) a method for producing an ester compound or an amide compound from a carboxylic acid equivalent and an alcohol or an amine, 2) an asymmetric esterification reaction or 3) an asymmetric amidation reaction.

Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.

Abstract: The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, ?, and ? are each integers whose values are independently selected. Alternatively, the linker structure may have the following structure: wherein ? and ? are each integers whose values are independently selected.

Abstract: Universal supports for oligonucleotide synthesis include a support material represented by the following formula: In this formula, substituent A is selected from H, alkyl, aryl, or a polymeric or silica base material; substituent B is selected from acyl, aroyl, or a polymeric or silica base material; and substituent C is selected from a dimethoxytrityl group or a protecting group removable under acidic or neutral conditions. For the supports, one of substituents A or B constitutes the polymeric or silica base material. In use, an oligonucleotide is attached to the support at substituent C.

Abstract: D-(threo)-1-aryl-2-disubstitutedacylamido-3-fluoro-1-propanol compounds compounds and analogues thereof (“Fenicol Compounds”), compositions comprising an effective amount of a Fenicol Compound, and methods for treating or preventing a bacterial infection in an animal comprising administering to an animal in need thereof an effective amount of a Fenicol Compound are disclosed.

Abstract: Novel cyclohexyl-1,4-diamine compounds corresponding to formula I, processes for the production thereof, pharmaceutical compositions containing these compounds, methods of producing pharmaceutical compositions including these compounds and related methods of treating or inhibiting certain diseases or conditions.

Abstract: An indaniline dye represented by the following formula (1): wherein R1 and R2 represent an unsubstituted linear or branched alkyl group having from 2 to 5 carbon atoms; R3 represents an unsubstituted linear or branched alkyl group having from 1 to 3 carbon atoms; provided that the total number of the carbon atoms of R1, R2 and R3 is 6 or 7.

Abstract: Dicyano alkanoic acid amides of formula (I), wherein R1 is H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or haloalkynyl; R2 is H, CN, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, alkoxy, or haloalkoxy; R3 and R4 are H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, cycloalkenyl, halocycloalkenyl, or R3 and R4 together can be alkylene, haloalkylene, alkenylene or haloalkenylene; X is O or S; R5 and R6 are H, alkyl, optionally substituted with 1 to 3 groups CN, NO2, OH, NR7R8, alkoxy, haloalkoxy, alkylthio, haloalkylthio, cycloalkyl, halocycloalkyl and optionally substituted phenyl; or haloalkyl, cycloalkyl, halocycloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, NR7R8, alkoxycarbonyl, haloalkoxycarbonyl, alkenyloxycarbonyl, haloalkenyloxycarbonyl, alkylcarbonyl, haloalkylcarbonyl, R7R8N—C(?O)—, phenylcarbonyl, benzylcarbonyl or phenyl wherein phen

Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Abstract: The invention relates to new protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use of the new compounds for the production of epothilones or epothilone derivatives.

Abstract: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.